Published in J Biol Chem on October 20, 2010
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell (2015) 2.20
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature (2012) 1.62
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood (2012) 1.31
Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem (2011) 1.16
PepSite: prediction of peptide-binding sites from protein surfaces. Nucleic Acids Res (2012) 1.13
Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS One (2013) 1.05
High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J Med Chem (2014) 0.89
Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. Cancers (Basel) (2012) 0.83
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Mol Cell (2015) 0.81
The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV. Blood (2014) 0.80
Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner. Leukemia (2015) 0.79
Challenges and opportunities in targeting the menin-MLL interaction. Future Med Chem (2014) 0.79
The role of HTS in drug discovery at the University of Michigan. Comb Chem High Throughput Screen (2014) 0.78
Detection of disordered regions in globular proteins using ¹³C-detected NMR. Protein Sci (2012) 0.77
Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes. J Med Chem (2015) 0.77
Identifying new targets in leukemogenesis using computational approaches. Saudi J Biol Sci (2015) 0.75
Targeting human SET1/MLL family of proteins. Protein Sci (2017) 0.75
Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem (2016) 0.75
Menin and Daxx Interact to Control Neuroendocrine Tumors via Epigenetic Regulation of Membrane Metallo-Endopeptidase. Cancer Res (2016) 0.75
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget (2016) 0.75
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR (1995) 93.94
MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph (1996) 39.73
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
Altered Hox expression and segmental identity in Mll-mutant mice. Nature (1995) 6.60
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol (2004) 6.55
Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell (1992) 6.11
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08
Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A (2005) 5.53
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2004) 3.62
MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell (2010) 2.29
Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer (2005) 1.87
Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res (2007) 1.82
Mechanisms of transformation by MLL. Crit Rev Eukaryot Gene Expr (2004) 1.70
The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci U S A (2006) 1.67
The bithorax complex is regulated by trithorax earlier during Drosophila embryogenesis than is the Antennapedia complex, correlating with a bithorax-like expression pattern of distinct early trithorax transcripts. Development (1994) 1.58
Protonless NMR experiments for sequence-specific assignment of backbone nuclei in unfolded proteins. J Am Chem Soc (2006) 1.54
When epigenetics kills: MLL fusion proteins in leukemia. Hematol Oncol (2005) 1.46
Infant leukaemia biology, aetiology and treatment. Leukemia (1996) 1.31
Exchange-transferred NOE spectroscopy and bound ligand structure determination. Curr Opin Struct Biol (2003) 1.27
Complete assignment of heteronuclear protein resonances by protonless NMR spectroscopy. Angew Chem Int Ed Engl (2005) 1.22
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. Am J Clin Pathol (2004) 1.12
Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest (1994) 1.10
The role of the MLL gene in infant leukemia. Int J Hematol (2003) 1.04
H-start for exclusively heteronuclear NMR spectroscopy: the case of intrinsically disordered proteins. J Magn Reson (2009) 0.90
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
The DCX-domain tandems of doublecortin and doublecortin-like kinase. Nat Struct Biol (2003) 2.22
NMR solution structure of the integral membrane enzyme DsbB: functional insights into DsbB-catalyzed disulfide bond formation. Mol Cell (2008) 1.92
An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain. PLoS One (2010) 1.52
MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A (2008) 1.50
Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell (2007) 1.43
A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther (2013) 1.42
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood (2012) 1.31
The binding of the PDZ tandem of syntenin to target proteins. Biochemistry (2006) 1.19
High resolution structure of the HDGF PWWP domain: a potential DNA binding domain. Protein Sci (2005) 1.19
Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure (2012) 1.18
Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem (2011) 1.16
The dimerization mechanism of LIS1 and its implication for proteins containing the LisH motif. J Mol Biol (2006) 1.12
Identification of infants with significant refractive error and strabismus in a population screening program using noncycloplegic videorefraction and orthoptic examination. Invest Ophthalmol Vis Sci (2003) 1.07
Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS One (2013) 1.05
On the mechanism of autoinhibition of the RhoA-specific nucleotide exchange factor PDZRhoGEF. BMC Struct Biol (2009) 1.04
The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. J Med Chem (2003) 1.03
Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias. Cancer Res (2012) 1.01
Ash1l controls quiescence and self-renewal potential in hematopoietic stem cells. J Clin Invest (2015) 1.00
Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. Blood (2009) 0.98
3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation. J Med Chem (2014) 0.96
Profiling the dynamic interfaces of fluorinated transcription complexes for ligand discovery and characterization. ACS Chem Biol (2012) 0.94
Sekikaic acid and lobaric acid target a dynamic interface of the coactivator CBP/p300. Angew Chem Int Ed Engl (2012) 0.90
High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J Med Chem (2014) 0.89
Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells. Cancer Res (2013) 0.86
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest (2016) 0.86
An evolution-based approach to De Novo protein design and case study on Mycobacterium tuberculosis. PLoS Comput Biol (2013) 0.85
Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity. J Mol Biol (2010) 0.83
Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases. J Med Chem (2012) 0.83
Structural features and chaperone activity of the NudC protein family. J Mol Biol (2011) 0.81
Importance of alpha-helix N-capping motif in stabilization of betabetaalpha fold. Protein Sci (2003) 0.78
Inhibition of CDC25B phosphatase through disruption of protein-protein interaction. ACS Chem Biol (2014) 0.77
Detection of disordered regions in globular proteins using ¹³C-detected NMR. Protein Sci (2012) 0.77
Solution NMR studies reveal no global flexibility in the catalytic domain of CDC25B. Proteins (2014) 0.77
Assignment of 1H, 13C and 15N resonances of the N-terminal microtubule-binding domain of human doublecortin. J Biomol NMR (2003) 0.75